Dosing equation for tacrolimus using genetic variants and clinical factors

British Journal of Clinical Pharmacology

Volumn 72, Issue 6, 2011, Pages 948-957

  Passey, Chaitali ^a   Birnbaum, Angela K ^a   Brundage, Richard C ^a   Oetting, William S ^a   Israni, Ajay K ^b   Jacobson, Pamala A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

CYP3A5; Kidney transplantation; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics; Tacrolimus

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; TACROLIMUS;

ADULT; AGE; ARTICLE; BODY WEIGHT; DRUG CLEARANCE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS; UNITED STATES;

EID: 80855131391     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04039.x     Document Type: Article

References (52)

1. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother 2008; 9: 635-43.
2. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31: 139-52.
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-53.
4. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62: 900-5.
5. Borobia AM, Romero I, Jimenez C, Gil F, Ramirez E, De Gracia R, Escuin F, Gonzalez E, Sansuan AJ. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436-42.
6. O'Seaghdha CM, McQuillan R, Moran AM, Lavin P, Dorman A, O'Kelly P, Mohan DM, Little P, Hickey DP, Conlon PJ. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. Clin Transplant 2009; 23: 462-8.
7. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-9.
8. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, Andre JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 2009; 86: 609-18.
9. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64: 750-7.
10. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660-9.
11. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103: 546-52.
12. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141-75.
13. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228-34.
14. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914-9.
15. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, Li LS. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19: 638-43.
16. Pascual J, Galeano C, Royuela A, Zamora J. A Systematic Review on Steroid Withdrawal Between 3 and 6 Months After Kidney Transplantation. Transplantation 2010; 90: 343-9.
17. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-6.
18. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
19. Hardenbol P, Baner J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, Fakhrai-Rad H, Ronaghi M, Willis TD, Landegren U, Davis RW. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003; 21: 673-8.
20. Jacobson PA, Oetting WS, Brearley A, Leduc R, Guan W, Schladt D, Matas AJ, Lamba V, Julian B, Mannon R, Israni I. Novel polymorphisms associated with tacrolimus trough concentrations: results from a Multicenter Kidney Transplant Consortium. Transplantation 2011; 91: 300-8.
21. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, Mekki QA. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-90.
22. Wallemacq PE, Furlan V, Moller A, Schafer A, Stadler P, Firdaous I, Taburet AM, Reding R, De Clety C, De S, De Goyet J, Sokal E, Lykavieris L, Van Leeuw V, Bernard O, Otte JB, Undre NA. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998; 23: 367-70.
23. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130-7.
24. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, Miura M, Suzuki T, Kato T, Habuchi T. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37: 1730-2.
25. Pou L, Brunet M, Andres I, Rodamilans M, Lopez R, Corbella J. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 1998; 11 (Suppl. 1): S270-1.
26. Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, Shin WG. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 2006; 26: 1069-77.
27. Antignac M, Fernandez C, Barrou B, Roca M, Favrat JL, Urien S, Farinotti R. Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. Eur J Drug Metab Pharmacokinet 2011; 36: 25-33.
28. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94.
29. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-72.
30. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.
31. Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, Kamar N, Marquet P, Rousseau A. Population pharmacokinetics and bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010; 49: 683-92.
32. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182-7.
33. Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q, Wang W. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005; 37: 178-81.
34. Wang P, Mao Y, Zhou X, Wong TS, Patel S, Elliott E, Shea E, Wu HA, Gaber AO. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 2010; 11: 1389-402.
35. Suzuki Y, Homma M, Doki K, Itagaki F, Kohda Y. Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects. Br J Clin Pharmacol 2008; 66: 154-5.
36. Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations - twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol 2011; 71: 391-402.
37. Satoh S. CYP3A5 1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur J Clin Pharmacol 2009; 65: 473-81.
38. Hesselink DA. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339-48.
39. Israni A, Leduc R, Holmes J, Jacobson PA, Lamba V, Guan W, Schladt D, Chen J, Matas AJ, Oetting WS. Single-nucleotide polymorphisms, acute rejection, and severity of tubulitis in kidney transplantation, accounting for center-to-center variation. Transplantation 2010; 90: 1401-8.
40. Matas AJ. Minimization of steroids in kidney transplantation. Transpl Int 2009; 22: 38-48.
41. Li L, Weintraub L, Concepcion W, Martin JP, Miller K, Salvatierra O, Sarwal MM. Potential influence of tacrolimus and steroid avoidance on early graft function in pediatric renal transplantation. Pediatr Transplant 2008; 12: 701-7.
42. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
43. El-Sankary W, Plant NJ, Gibson GG, Moore DJ. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos 2000; 28: 493-6.
44. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000; 68: 356-66.
45. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998; 30: 1261-3.
46. Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 2008; 42: 1037-47.
47. Velickovic-Radovanovic R, Catic-Djordjevic A, Milovanovic JR, Djordjevic V, Paunovic G, Jankovic SM. Population pharmacokinetics of tacrolimus in kidney transplant patients. Int J Clin Pharmacol Ther 2010; 48: 375-82.
48. Li JL, Wang XD, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX, Huang M. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J 2010; doi: 10.1038/tpj.2010.42.
49. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33: 680-2.
50. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125-30.
51. Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M, Nappi R, Ciotola A, D'Alessandro V, Renda A, Basile V, Federico S. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther 2010; 35: 121-4.
52. Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 1997; 25: 1430-40.